If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]
– Presentation, in the form of a poster, of the updated data from the phase 1 study, rESPECT, with eryaspase plus mFOLFIRINOX in front-line pancreatic cancer patients, confirming a good safety profile and demonstrating encouraging clinical activity
– Oral presentation of the complete results of the phase 3 TRYbeCA-1 study with eryaspase in the second-line treatment of metastatic pancreatic cancer, as a ‘late-breaking’ abstract, confirming the first results communicated in October 2021, and highlighting the potential benefit of eryaspase in a subgroup of patients treated with FOLFIRI
ERYTECH Pharma (Euronext: ERYP; Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drugs in red blood cells (RBCs), today announced the presentation of results from two studies evaluating eryaspase in the treatment of advanced pancreatic cancer at the American Society of Clinical Oncology (ASCO GI) Gastrointestinal Cancer Symposium on January 21, 2022.